Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD.
Identifieur interne : 000E61 ( Main/Corpus ); précédent : 000E60; suivant : 000E62Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD.
Auteurs : S. Sebastian ; H A Gonzalez ; L. Peyrin-BirouletSource :
- Journal of Crohn's & colitis [ 1876-4479 ] ; 2020.
Abstract
The Coronavirus 2019 (COVID-19) pandemic has posed challenges in the routine care of patients with inflammatory bowel disease. One of the key challenges needing addressing is the quantification of the risks of immunosuppressive and biologic therapies in IBD patients during the pandemic. The similarities and differences between the previous coronavirus outbreaks and the pathobiology of the infections can give useful information in understanding the risks, and perhaps potential beneficial aspects of drugs used in IBD. Although clinical, immunological and pharmacological data from the experience with the previous coronavirus outbreaks cannot be automatically translated to predict the safety of IBD therapies during COVID-19 pandemic, the signals so far from these outbreaks on IBD patients who are on immunomodulators and biologics are reassuring to patients and clinicians alike.
DOI: 10.1093/ecco-jcc/jjaa120
PubMed: 32520312
PubMed Central: PMC7314090
Links to Exploration step
pubmed:32520312Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD.</title><author><name sortKey="Sebastian, S" sort="Sebastian, S" uniqKey="Sebastian S" first="S" last="Sebastian">S. Sebastian</name><affiliation><nlm:affiliation>IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Hull York Medical School, Hull, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez, H A" sort="Gonzalez, H A" uniqKey="Gonzalez H" first="H A" last="Gonzalez">H A Gonzalez</name><affiliation><nlm:affiliation>IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Peyrin Biroulet, L" sort="Peyrin Biroulet, L" uniqKey="Peyrin Biroulet L" first="L" last="Peyrin-Biroulet">L. Peyrin-Biroulet</name><affiliation><nlm:affiliation>Department of Gastroenterology, Nancy University Hospital, Vandoeuvre-Les-Nancy, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Inserm U1256 NGERE, Lorraine University, Vandoeuvre-Les-Nancy, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32520312</idno><idno type="pmid">32520312</idno><idno type="doi">10.1093/ecco-jcc/jjaa120</idno><idno type="pmc">PMC7314090</idno><idno type="wicri:Area/Main/Corpus">000E61</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000E61</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD.</title><author><name sortKey="Sebastian, S" sort="Sebastian, S" uniqKey="Sebastian S" first="S" last="Sebastian">S. Sebastian</name><affiliation><nlm:affiliation>IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Hull York Medical School, Hull, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez, H A" sort="Gonzalez, H A" uniqKey="Gonzalez H" first="H A" last="Gonzalez">H A Gonzalez</name><affiliation><nlm:affiliation>IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Peyrin Biroulet, L" sort="Peyrin Biroulet, L" uniqKey="Peyrin Biroulet L" first="L" last="Peyrin-Biroulet">L. Peyrin-Biroulet</name><affiliation><nlm:affiliation>Department of Gastroenterology, Nancy University Hospital, Vandoeuvre-Les-Nancy, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Inserm U1256 NGERE, Lorraine University, Vandoeuvre-Les-Nancy, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of Crohn's & colitis</title><idno type="eISSN">1876-4479</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Coronavirus 2019 (COVID-19) pandemic has posed challenges in the routine care of patients with inflammatory bowel disease. One of the key challenges needing addressing is the quantification of the risks of immunosuppressive and biologic therapies in IBD patients during the pandemic. The similarities and differences between the previous coronavirus outbreaks and the pathobiology of the infections can give useful information in understanding the risks, and perhaps potential beneficial aspects of drugs used in IBD. Although clinical, immunological and pharmacological data from the experience with the previous coronavirus outbreaks cannot be automatically translated to predict the safety of IBD therapies during COVID-19 pandemic, the signals so far from these outbreaks on IBD patients who are on immunomodulators and biologics are reassuring to patients and clinicians alike.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32520312</PMID><DateRevised><Year>2020</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-4479</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Jun</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of Crohn's & colitis</Title><ISOAbbreviation>J Crohns Colitis</ISOAbbreviation></Journal><ArticleTitle>Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">jjaa120</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ecco-jcc/jjaa120</ELocationID><Abstract><AbstractText>The Coronavirus 2019 (COVID-19) pandemic has posed challenges in the routine care of patients with inflammatory bowel disease. One of the key challenges needing addressing is the quantification of the risks of immunosuppressive and biologic therapies in IBD patients during the pandemic. The similarities and differences between the previous coronavirus outbreaks and the pathobiology of the infections can give useful information in understanding the risks, and perhaps potential beneficial aspects of drugs used in IBD. Although clinical, immunological and pharmacological data from the experience with the previous coronavirus outbreaks cannot be automatically translated to predict the safety of IBD therapies during COVID-19 pandemic, the signals so far from these outbreaks on IBD patients who are on immunomodulators and biologics are reassuring to patients and clinicians alike.</AbstractText><CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sebastian</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hull York Medical School, Hull, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>H A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peyrin-Biroulet</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Nancy University Hospital, Vandoeuvre-Les-Nancy, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm U1256 NGERE, Lorraine University, Vandoeuvre-Les-Nancy, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Crohns Colitis</MedlineTA><NlmUniqueID>101318676</NlmUniqueID><ISSNLinking>1873-9946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32520312</ArticleId><ArticleId IdType="pii">5855542</ArticleId><ArticleId IdType="doi">10.1093/ecco-jcc/jjaa120</ArticleId><ArticleId IdType="pmc">PMC7314090</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E61 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000E61 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32520312
|texte= Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32520312" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |